These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16112423)

  • 1. Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.
    Mocanu MM; Fazekas Z; Petrás M; Nagy P; Sebestyén Z; Isola J; Tímár J; Park JW; Vereb G; Szöllosi J
    Cancer Lett; 2005 Sep; 227(2):201-12. PubMed ID: 16112423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
    Nagy P; Friedländer E; Tanner M; Kapanen AI; Carraway KL; Isola J; Jovin TM
    Cancer Res; 2005 Jan; 65(2):473-82. PubMed ID: 15695389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
    Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
    Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-sided fluorescence resonance energy transfer for assessing molecular interactions of up to three distinct species in confocal microscopy.
    Fazekas Z; Petrás M; Fábián A; Pályi-Krekk Z; Nagy P; Damjanovich S; Vereb G; Szöllosi J
    Cytometry A; 2008 Mar; 73(3):209-19. PubMed ID: 18044751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2.
    Nagy P; Vereb G; Sebestyén Z; Horváth G; Lockett SJ; Damjanovich S; Park JW; Jovin TM; Szöllosi J
    J Cell Sci; 2002 Nov; 115(Pt 22):4251-62. PubMed ID: 12376557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer.
    Lesniak D; Xu Y; Deschenes J; Lai R; Thoms J; Murray D; Gosh S; Mackey JR; Sabri S; Abdulkarim B
    Cancer Res; 2009 Nov; 69(22):8620-8. PubMed ID: 19887601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
    Pályi-Krekk Z; Barok M; Isola J; Tammi M; Szöllosi J; Nagy P
    Eur J Cancer; 2007 Nov; 43(16):2423-33. PubMed ID: 17911008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
    Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression.
    Henson ES; Hu X; Gibson SB
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):845-53. PubMed ID: 16467098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
    Yuste L; Montero JC; Esparís-Ogando A; Pandiella A
    Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lubrol-RAFTs in melanoma cells: a molecular platform for tumor-promoting ephrin-B2-integrin-beta1 interaction.
    Meyer S; Orsó E; Schmitz G; Landthaler M; Vogt T
    J Invest Dermatol; 2007 Jul; 127(7):1615-21. PubMed ID: 17380111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor.
    Troise F; Cafaro V; Giancola C; D'Alessio G; De Lorenzo C
    FEBS J; 2008 Oct; 275(20):4967-79. PubMed ID: 18795950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
    Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE; Serrero G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.
    Kang SH; Kang KW; Kim KH; Kwon B; Kim SK; Lee HY; Kong SY; Lee ES; Jang SG; Yoo BC
    BMC Cancer; 2008 Oct; 8():286. PubMed ID: 18834540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.